Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-CC5: Biomarker Study of FTD/TPI Plus Bevacizumab as Salvage Chemotherapy for Colorectal Cancer
jRCT1031220613Recruiting
- Sponsor
- Takeshi Yamada
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of trifluridine + tipiracil and bevacizumab in colorectal cancer (CRC), sponsored by Takeshi Yamada. Primary endpoint: progression-free survival. Started Nov 2022; status: recruiting.
02
Drugs
trifluridine + tipiracilbevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT1031220613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031220613.